Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04105010 · OUTCOME

Part B: Complete Response Rate (CRR) Assessed by IRC

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) · Source last updated 2025-04-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 3 years

What was measured

CRR is the percentage of patients with at least one visit response of CR based on CT scans evaluated by IRC per Lugano criteria.

Analysis population: Evaluable for CT-based Response Set

Groups in this outcome

AZD4205 Group D

Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD4205 Group D102

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD4205 Group D21.6Not reported14.030.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        14.0
        upper Limit
        30.8
        value
        21.6
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
CRR is the percentage of patients with at least one visit response of CR based on CT scans evaluated by IRC per Lugano criteria.
dispersion Type
95% Confidence Interval
groups
  1. description
    Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2) AZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
    id
    OG000
    title
    AZD4205 Group D
param Type
NUMBER
population Description
Evaluable for CT-based Response Set
reporting Status
POSTED
time Frame
Up to approximately 3 years
title
Part B: Complete Response Rate (CRR) Assessed by IRC
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice